In the event of severe adverse reactions, patients should promptly inform their healthcare provider or seek medical assistance to ensure their personal safety
As of June 2026, BPC-157, TB-500, CJC-1295, semax, and epitalon have all reportedly been removed from the FDAs 503A Category 2 compounding-restriction list but none were moved to Category 1 and none are FDA-approved , leaving them in an actively-changing regulatory gray zone
Tirzepatide works as a dual agonist targeting GLP-1 and GIP receptors while retatrutide works on glucagon receptors as a third mechanism
2400mg: This is the highest dose among the options, providing four times the amount of the compound as the 600mg dose
2024 Apr 19.
Stay well-hydrated, maintain a balanced diet, engage in regular physical activity, and protect your skin from excessive sun exposure